Tuberkulose – nach wie vor aktuell

R. Loddenkemper

DOI: https://doi.org/10.1007/s10405-010-0408-z

Der Pneumologe

Abstract:

What problem does this paper attempt to address?

Impact Clinically Related Factors on the Outcomes of Ventilator-Associated Pneumonia

Pan Zhou,Hong He,Jing-dong Liu,Xiao-hong Wu

DOI: https://doi.org/10.3760/j.issn:0254-6450.2003.03.015

2003-01-01

Abstract:OBJECTIVE:To define the influence clinically related factors in the prognosis of ventilated pneumonia (VAP).METHODS:A prospective clinical study involving 120 patients with VAP was carried ont. Etiologic diagnosis was established under quantitative culture of endotracheal aspiration, a protected specimen brush and bronchoalveolar lavage. Prognostic using a statistical software package (SPSS) factors were examined for univariate and multivariate analyses.RESULTS:Case fatality directly related to the infection was 14 percent. From univariate analysis, variables that significantly associated with attributable mortality were age older than 45 years, use of corticosteroids, presence of shock, in-hospital days of VAP over as follows 9, antecedent chronic obstructive pulmonary disease, and a prior antibiotic use. Through step-forward logistic regression analysis, only prior antibiotic use (P < 0.000 1, OR = 9.2) was defined as a significant factor influencing the risk of death from VAP. The same result was obtained when severity was included in the model. However, prior antibiotic use entirely dropped out as a significant risk factor when the etiologic agent was included in the regression equation.CONCLUSIONS:Distribution of microorganisms that responsible for VAP shown different in patients who had received prior antimicrobial therapy, and this factor caused higher mortality rate. We suggested a restrictive antibiotic use strategy among mechanically ventilated patients to reduce the risk of death from VAP.
Do Probiotics Help Prevent Ventilator-Associated Pneumonia In Critically Ill Patients? A Systematic Review With Meta-Analysis

Jie Zhao,Lei-qing Li,Cheng-yang Chen,Gen-sheng Zhang,Wei Cui,Bao-ping Tian

DOI: https://doi.org/10.1183/23120541.00302-2020

IF: 4.239

2021-01-01

ERJ Open Research

Abstract:Background: Probiotic treatments might contribute to the prevention of ventilator-associated pneumonia (VAP). Due to its unclear clinical effects, here we intend to assess the preventive effect and safety of probiotics on intensive care unit (ICU) patients.Methods: Eligible randomised controlled trials were selected in databases until 30 September 2019. The characteristics of the studies were extracted, including study design, definition of VAP, probiotics intervention, category of included patients, incidence of VAP, mortality, duration of mechanical ventilation (MV) and ICU stay. Heterogeneity was evaluated by Chi-squared and I2 tests.Results: 15 studies involving 2039 patients were identified for analysis. The pooled analysis suggests significant reduction on VAP (risk ratio, 0.68; 95% Cl, 0.60 to 0.77; p<0.00001) in a fixed-effects model. Subgroup analyses performed on the category of clinical and microbiological criteria both support the above conclusion; however, there were no significant differences in duration of MV or length of ICU stay in a random-effects model. Also, no significant differences in total mortality, overall mortality, 28-day mortality or 90-day mortality were found in the fixed-effects model.Conclusions: The probiotics helped to prevent VAP without impacting the duration of MV, length of ICU stay or mortality.
Fiberoptic bronchoscopy for the prevention of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials

Haowei Tang,Zhi Yuan,Jingjie Li,Qun Wang,Weijie Fan

DOI: https://doi.org/10.3855/jidc.17866

2024-10-21

The Journal of Infection in Developing Countries

Abstract:Introduction: Ventilator-associated pneumonia (VAP) causes increased time of mechanical ventilation (MV), prolonged intensive care unit (ICU) stay, and a higher mortality risk. The systematic review and meta-analysis aimed to compare the efficacies between fiberoptic bronchoscopy (FOB) and general sputum suction for the prevention of VAP in patients with invasive MV. Methodology: Relevant randomized controlled trials (RCTs) were obtained via a search of PubMed, Embase, Cochrane Library, Wanfang, and CNKI databases. A random-effects model was used to pool the results if significant heterogeneity was observed. Otherwise, a fixed-effects model was used. Results: Sixteen RCTs were included. Compared to general sputum suction, sputum suction with FOB was associated with a significantly reduced risk of VAP (risk ratio [RR]: 0.56, 95% CI: 0.47 to 0.67, p < 0.001; I 2 = 0%). Subgroup analyses showed that the combination of FOB-assisted sputum suction with bronchoalveolar lavage (BAL) further reduced the risk of VAP as compared to FOB-assisted sputum suction alone (p for subgroup difference = 0.04). In addition, FOB-assisted treatment was also associated with a reduced MV time (mean difference [MD]: -2.19 days, 95% CI: -2.69 to -1.68, p < 0.001; I 2 = 18%), a shorter ICU stay (MD: 2.9 days, 95% CI: -3.68 to -2.13, p < 0.001; I 2 = 34%), and a reduced mortality risk (RR: 0.46, 95% CI: 0.24 to 0.90, p = 0.02; I 2 = 0%) in patients with invasive MV. Conclusions: FOB for sputum suction and BAL in patients with invasive MV is effective in reducing the incidence of VAP.

infectious diseases
Effect of bronchoalveolar lavage on the use of antibiotics in patients with severe pneumonia

Feifei Shao,Qiqiang Liang,Wei Xiao,Man Huang

DOI: https://doi.org/10.3760/cma.j.issn.1671-0282.2019.12.014

2019-01-01

Abstract:Objective To investigate the difference between bronchoalveolar lavage fluid(BALF)and tracheal aspirate(TA)on the use of antibiotics in patients with severe pneumonia.Methods Patients with severe pneumonias admitted to the Department of General Intensive Care Unit of Second Affiliated Hospital of Zhejiang University School of Medicine,between December 2014 and March 2019 were retrospectively analyzed.The difference of effects of BLAF and TA on the use of antibiotics in patients with severe pneumonia were compared and analyzed,as well as the effects of antibiotic de-escalation on patient's mortality were evaluated.The quantitative data were analyzed by independent sample t test and the enumeration data were determined by Chi-square test or Fisher exact probability method.Results Among the 120 patients more bacteria were detected in BALF than in TA(82 vs 60,P＜0.05).More fungi were detected in BALF than in TA(20 vs 3,P＜0.05).Compared with TA,BALF results were more likely to guide the adjustment of antibiotic regimens(41 vs 16,P＜0.05),including guidance for antibiotics de-escalation(27 vs 9,P＜0.05).There was no significant difference in the 14-day mortality,28-day mortality,hospital stay and duration of mechanical ventilation between the two groups(al P＜0.05).Conclusions Compared with TA,BALF,as a pathogens detection method for severe pneumonia,has more advantages in guiding antibiotics administration,including antibiotic de-escalation,which will not increase the mortality of patients.
Long-term Control of Intractable Supraventricular Tahycardia by Ventricular Pacing TABLE II 701 DRUG AND PACEMAKER TREATMENT

E. Sowton,R. Balcon,T. Preston,D. Leaver,M. Yacoub

Abstract:The prevention of rapid dysrhythmias in patients without heart block by pacing the heart above a critical rate has been utilized on a short-time basis for some years, particularly in patients with recent cardiac infarction (Sowton, Leatham, and Carson, 1964; Heiman and Helwig, 1966), or in those who have undergone cardiac surgery (Eraklis, Green, and Watson, 1965). The technique of overdriving in this way is usually applied only as a temporary measure but is applicable also to the long-term treatment of patients with tachycardia (Sowton, 1968; Burchell and Meredith, 1969; Dack, 1969). In this report we describe our clinical experience over the past two years with this method of treatment of supraventricular tachycardia.
The preventive effect of inhaled antibiotic against ventilator-associated pneumonia: a systematic review and meta-analysis

Wan-Hsuan Hsu,Jheng-Yan Wu,Bo-Wen Shiau,Po-Yu Huang,Min-Hsiang Chuang,Ya-Wen Tsai,Ting-Hui Liu,Hung-Jen Tang,Chih-Cheng Lai

DOI: https://doi.org/10.1016/j.ijantimicag.2024.107324

2024-09-05

Abstract:Background: Ventilator-associated pneumonia (VAP) constitutes a considerable challenge for patients in intensive care units (ICUs) and necessitates the development of effective preventive strategies. This study aimed to evaluate the clinical efficacy of inhaled antibiotics for preventing VAP. Methods: PubMed, Embase, and ClinicalTrials.gov were searched until January 21, 2024. Randomized controlled trials (RCTs) investigating the clinical efficacy of inhaled antibiotics for VAP prevention were included. Results: Seven RCTs, involving 1465 patients, of whom 734 were classified as the study group receiving inhaled antibiotics and 731 as the control group receiving placebo were included in this meta-analysis. Overall, the occurrence of VAP was significantly lower in the study group than in the control group (risk ratio [RR], 0.69; 95% confidence interval [CI], 0.51 to 0.92). However, there were no significant differences in mortality (RR, 0.90; 95% CI, 0.74 to 1.09), length of stay in ICU (mean difference [MD], 0.10 days; 95% CI, -0.91 to 1.1) and hospital (MD, 0.30 days; 95% CI, -1.82 to 2.43), and mechanical ventilation (MV) duration (MD, 0.45 days; 95% CI, -0.45 to 1.35) between groups. Conclusion: Inhaled antibiotics hold promise for mitigating the risk of VAP among critically ill patients. However, their impact on mortality, length of stay in ICU and hospital, and MV duration was not statistically significant.
Probiotics For Preventing Ventilator-Associated Pneumonia: A Systematic Review And Meta-Analysis Of High-Quality Randomized Controlled Trials

Jie Wang,Kai-Xiong Liu,Felinda Ariani,Li-Li Tao,Jing Zhang,Jie-Ming Qu

DOI: https://doi.org/10.1371/journal.pone.0083934

IF: 3.7

2013-01-01

PLoS ONE

Abstract:Background: Ventilator-associated pneumonia (VAP) is considered to be a worldwide issue along with the development of supportive ventilation. The preventing strategy is of great importance for its poor prognostic and difficulties in treatment. Probiotics have been advocated as one of the possible preventive measures. We conducted a systematic review and meta-analysis to explore the potential benefits of probiotics.Methods: The databases, Web of science, PubMed, Ovid and Cochrane lib were searched for randomized controlled trials (RCTs) publications that compared the effectiveness of probiotics with placebo in the prevention of VAP. The incidence of VAP was considered as the primary endpoint, mortality, length of stay in intensive care units (ICUs), etiology of the infections were considered as secondary endpoints.Results: A total of 844 patients from 5 trials were subjected to meta-analysis. Probiotics did not significantly decrease the incidence of VAP (RR 0.94, 95%CI 0.85-1.04, p=0.22), however, the administration of probiotics reduced the risk of VAP caused by Pseudomonas aeruginosa (P. aeruginosa) (RR 0.30, 95%CI 0.11-0.91, P=0.03). It failed to affect any other endpoints.Conclusion: Probiotic prophylaxis of ventilator-associated pneumonia remained inconclusive and it failed to improve the prognosis of general mechanically ventilated patients. It was noteworthy that infections caused by P. aeruginosa was reduced by administration of probiotics. In further, it is recommended that advanced studies should exploit transformation in pathogenic microorganisms owing to administration of probiotics as well as the specific population.
Effectiveness and safety of adjunctive inhaled antibiotics for ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials

Rui Tang,Rui Luo,Bin Wu,Fuping Wang,Haoxin Song,Xiujuan Chen

DOI: https://doi.org/10.1016/j.jcrc.2021.06.004

IF: 4.298

2021-10-01

Journal of Critical Care

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Introduction</h3><p>The efficacy and safety of adjunctive inhaled antibiotic therapy for ventilator-associated pneumonia (VAP) was systematically reviewed based on updated studies.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We searched four databases and four clinical trial registration platforms to identify relevant studies published prior to May 19, 2020. Randomized controlled trials (RCTs) assessing adjunctive antibiotic inhalation treatment for VAP patients were eligible for this review. Two reviewers independently screened the articles and extracted the data. Information on inhaled therapy and clinical outcomes was collected. Study quality was assessed with the Cochrane risk of bias tool. The meta-analysis was conducted with Review Manager and R software. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines were used to evaluate the quality of evidence for each pooled outcome.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Eleven RCTs and 1210 patients were included in this analysis after the application of the inclusion and exclusion criteria. Compared with the use of intravenous injection alone, the use of adjunctive inhaled antibiotic therapy improved the rates of clinical cure (relative risk (RR) 1.13, 95% CI [1.02,1.26]) and microbiological eradication (RR 1.45, 95% CI [1.19,1.76]) in VAP patients. However, despite these improvements, mortality was not reduced (RR 1.00, 95% CI [0.82,1.21]). Adjunctive antibiotics delivered through the respiratory tract were not associated with a higher risk of renal impairment but were associated with an increased risk of bronchospasm (RR 2.74, 95% CI [1.31,5.73] during treatment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Adjunctive inhaled antibiotics improved the clinical outcomes in VAP patients, but the increased rates clinical cure and microbiological eradication were not associated with reduced mortality. The use of nebulized antibiotics is not supported by the currently available evidence as a routine therapeutic strategy for VAP.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">PROSPERO registration number</h3><p>CRD42020186970.</p>

critical care medicine
Analysis of the risk factors and pathogenic bacteria of ventilator-associated pneumonia

Ren-hui CHEN,Fu-zheng TAO,Ying-zi CHEN,Jun-qing WANG,Xi CHEN

DOI: https://doi.org/10.11816/cn.ni.2014-143823

2014-01-01

Abstract:OBJECTIVE To explore the risk factors of ventilator‐associated pneumonia and the distribution of the related pathogens ,so as to provide scientific evidence for the prevention and control of ventilator associated pneu‐monia. METHODS A retrospective analysis was conducted to 172 patients who were treated with mechanical venti‐lation in ICU from Feb. 2012 to Feb. 2014. The clinical features ,risk factors and the distribution of pathogens related to ventilator‐associated pneumonia were studied. All data were analyzed by SPSS 11. 0. RESULTS In 172 patients who were treated with mechanical ventilation ,78 were infected with ventilator‐associated pneumonia ,the incidence rate was 45. 35%. The sputum specimens of them were examined and 105 strains of pathogenic bacteria were found. Of them ,62 strains were gram‐negative bacilli ,accounting for 59. 05%. 27 strains were gram‐posi‐tive bacilli ,accounting for 25. 71%. 16 strains were fungi ,accounting for 15. 24%. The risk factors of ventilator‐associated pneumonia included age ,underlying diseases ,mechanical ventilation time ,and the existence of con‐sciousness disorder , tracheotomy , invasive operation , antibiotic application and duration of hospitalization. CONCLUSION There are many risk factors for ICU patients with ventilator‐associated pneumonia so we call for a strict ventilation index ,which can provide the corresponding nursing measures considering these risk factors. Strict implementation of aseptic management ,precaution of reflux and aspiration ,and rational use of antimicrobial drugs ,can effectively reduce the incidence of ventilator‐associated pneumonia.
[Interpretation of cholecystographic data].

J. Baumel

1950-09-01

Abstract:
Prophylactic Antibiotics Delivered Via the Respiratory Tract to Reduce Ventilator-Associated Pneumonia: A Systematic Review, Network Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials

Jie Li,Shan Lyu,Jian Luo,Ping Liu,Fai A Albuainain,Omar A Alamoudi,Violaine Rochette,Stephan Ehrmann

DOI: https://doi.org/10.1097/CCM.0000000000006323

2024-10-01

Abstract:Objectives: To assess the effects of antibiotics delivered via the respiratory tract in preventing ventilator-associated pneumonia (VAP). Data sources: We searched PubMed, Scopus, the Cochrane Library, and ClinicalTrials.gov for studies published in English up to October 25, 2023. Study selection: Adult patients with mechanical ventilation of over 48 h and receiving inhaled or instilled antibiotics (with control group) to prevent VAP were included. Data extraction: Two independent groups screened studies, extracted the data, and assessed the risk of bias. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to assess the certainty/quality of the evidence. Results of a random-effects model were reported for overall and predefined subgroup meta-analyses. The analysis was primarily conducted on randomized controlled trials, and observational studies were used for sensitivity analyses. Data synthesis: Seven RCTs with 1445 patients were included, of which six involving 1283 patients used nebulizers to deliver antibiotics. No obvious risk of bias was found among the included RCTs for the primary outcome. Compared with control group, prophylactic antibiotics delivery via the respiratory tract significantly reduced the risk of VAP (risk ratio [RR], 0.69 [95% CI, 0.53-0.89]), particularly in subgroups where aminoglycosides (RR, 0.67 [0.47-0.97]) or nebulization (RR, 0.64 [0.49-0.83]) were used as opposed to other antibiotics (ceftazidime and colistin) or intratracheal instillation. No significant differences were observed in mortality, mechanical ventilation duration, ICU and hospital length of stay, duration of systemic antibiotics, need for tracheostomy, and adverse events between the two groups. Results were confirmed in sensitivity analyses. Conclusions: In adult patients with mechanical ventilation for over 48 h, prophylactic antibiotics delivered via the respiratory tract reduced the risk of VAP, particularly for those treated with nebulized aminoglycosides.
Risk factors in patients with Acinetobacter baumanii ventilator-associated pneumonia

ZHOU Zhao-yang,ZHOU Jian-ying

DOI: https://doi.org/10.13381/j.cnki.cjm.2013.06.022

2013-01-01

Abstract:Objective To study the risk factors in patients with Acinetobacter baumannii ventilator-associated pneumonia(VAP) in intensive care unit in order to provide evidence for the prevention and treatment of VAP.Methods The related risk factors of VAP patients in intensive care unit during Jan 2008 to Dec 2011 were retrospectively analyzed.Statistical analysis was performed using SPSSversion 16.0.Results In the total 389 cases,112 were diagnosed as VAP.The morbidity of VAP was 28.2%.The mortality was 32.1%.The major factors were the score of APACHE II,the lasting time of mechanical ventilation,the way of mechanical ventilation,combination of antibiotics,coma,indwelling gastric tube,age,and corticosteroids.Conclution The occurrence of VAP is related to multiple clinical factors.Intensive monitoring of risk factors,strict bacteria-free operation and adoption of management bundle may help to reduce the occurrence of VAP.
Efficacy of preventive interventions against ventilator-associated pneumonia in critically ill patients: An umbrella review of meta-analyses

Dongwei Zhu,Qi Zhao,Shenhao Guo,Le Bai,Shuang Yang,Yisheng Zhao,Yong Xu,Xianmei Zhou

DOI: https://doi.org/10.1016/j.jhin.2023.12.017

IF: 8.944

2024-01-31

Journal of Hospital Infection

Abstract:Summary Background Many meta-analyses have assessed the efficacy of preventive interventions against ventilator-associated pneumonia (VAP) in critically ill patients. However, there has been no comprehensive analysis of the strength and quality of evidence to date. Methods Systematic reviews of randomized and quasi-randomized controlled trials, which evaluated the effect of preventive strategies on the incidence of VAP in critically ill patients receiving mechanical ventilation for at least 48 h, were enrolled in this article. Results We identified a sum of 34 interventions derived from 31 studies. Among these interventions, 19 resulted in a significantly reduced incidence of VAP. Among numerous strategies, only selective decontamination of the digestive tract (SDD) was supported by highly suggestive (class II) evidence (risk ratio [RR] = 0.439, 95% CI: 0.362, 0.532). Based on data from the sensitivity analysis, the evidence for the efficacy of non-invasive ventilation in weaning from mechanical ventilation (NIV) was upgraded from weak (class IV) to highly suggestive (class II) (RR = 0.32, 95% CI: 0.22, 0.46). All preventive interventions were not supported by robust evidence for reducing mortality. Early mobilization (EM) exhibited suggestive (class III) evidence in shortening both intensive length of stay (LOS) in the intensive care unit (ICU) (mean difference [MD] = -0.85, 95% CI: -1.21, -0.49) and duration of mechanical ventilation (MV) (MD = -1.02, 95% CI: -1.41, -0.63). Conclusions SDD and NIV are supported by robust evidence for prevention against VAP, while EM has been shown to significantly shorten the LOS in the ICU and the duration of MV. These three strategies are recommendable for inclusion in the ventilator bundle to lower the risk of VAP and improve the prognosis of critically ill patients.

infectious diseases,public, environmental & occupational health
Probiotics for the Prevention of Ventilator-Associated Pneumonia: A Meta-Analysis of Randomized Controlled Trials

Minmin Su,Ying Jia,Yan Li,Dianyou Zhou,Jinsheng Jia

DOI: https://doi.org/10.4187/respcare.07097

2020-03-03

Respiratory Care

Abstract:BACKGROUND:Ventilator-associated pneumonia (VAP) is a common and serious complication of mechanical ventilation. We conducted a meta-analysis of published randomized controlled trials to evaluate the efficacy and safety of probiotics for VAP prevention in patients who received mechanical ventilation.METHODS:We searched a number of medical literature databases to identify randomized controlled trials that compared probiotics with controls for VAP prevention. The results were expressed as odds ratios (OR) or mean differences with accompanying 95% CIs. Study-level data were pooled by using a random-effects model. Data syntheses were accomplished by using statistical software.RESULTS:Fourteen studies that involved 1,975 subjects met our inclusion criteria. Probiotic administration was associated with a reduction in VAP incidence among all 13 studies included in the meta-analysis (OR 0.62, 95% CI 0.45–0.85; P = .003; I2 = 43%) but not among the 6 double-blinded studies (OR 0.72, 95% CI 0.44–1.19; P = .20; I2 = 55%). We found a shorter duration of antibiotic use for VAP (mean difference −1.44, 95% CI −2.88 to −0.01; P = .048, I2 = 30%) in the probiotics group than in the control group, and the finding comes from just 2 studies. No statistically significant differences were found between the groups in terms of ICU mortality (OR 0.95, 95% CI 0.67–1.34; P = .77; I2 = 0%), ICU stay (mean difference –0.77, 95% CI –2.58 to 1.04; P = .40; I2 = 43%), duration of mechanical ventilation (mean difference –0.91, 95% CI –2.20 to 0.38; P = .17; I2 = 25%), or occurrence of diarrhea (OR 0.72, 95% CI 0.45–1.15; P = .17; I2 = 41%).CONCLUSIONS:The meta-analysis results indicated that the administration of probiotics significantly reduced the incidence of VAP. Furthermore, our findings need to be verified in large-scale, well-designed, randomized, multi-center trials.

respiratory system,critical care medicine
Diagnosis of ventilator-associated pneumonia in critically ill adult patients—a systematic review and meta-analysis

Shannon M. Fernando,Alexandre Tran,Wei Cheng,Michael Klompas,Kwadwo Kyeremanteng,Sangeeta Mehta,Shane W. English,John Muscedere,Deborah J. Cook,Antoni Torres,Otavio T. Ranzani,Alison E. Fox-Robichaud,Waleed Alhazzani,Laveena Munshi,Gordon H. Guyatt,Bram Rochwerg

DOI: https://doi.org/10.1007/s00134-020-06036-z

IF: 38.9

2020-04-18

Intensive Care Medicine

Abstract:The accuracy of the signs and tests that clinicians use to diagnose ventilator-associated pneumonia (VAP) and initiate antibiotic treatment has not been well characterized. We sought to characterize and compare the accuracy of physical examination, chest radiography, endotracheal aspirate (ETA), bronchoscopic sampling cultures (protected specimen brush [PSB] and bronchoalveolar lavage [BAL]), and CPIS > 6 to diagnose VAP. We searched six databases from inception through September 2019 and selected English-language studies investigating accuracy of any of the above tests for VAP diagnosis. Reference standard was histopathological analysis. Two reviewers independently extracted data and assessed study quality. We included 25 studies (1639 patients). The pooled sensitivity and specificity of physical examination findings for VAP were poor: fever (66.4% [95% confidence interval [CI]: 40.7–85.0], 53.9% [95% CI 34.5–72.2]) and purulent secretions (77.0% [95% CI 64.7–85.9], 39.0% [95% CI 25.8–54.0]). Any infiltrate on chest radiography had a sensitivity of 88.9% (95% CI 73.9–95.8) and specificity of 26.1% (95% CI 15.1–41.4). ETA had a sensitivity of 75.7% (95% CI 51.5–90.1) and specificity of 67.9% (95% CI 40.5–86.8). Among bronchoscopic sampling methods, PSB had a sensitivity of 61.4% [95% CI 43.7–76.5] and specificity of 76.5% [95% CI 64.2–85.6]; while BAL had a sensitivity of 71.1% [95% CI 49.9–85.9] and specificity of 79.6% [95% CI 66.2–85.9]. CPIS > 6 had a sensitivity of 73.8% (95% CI 50.6–88.5) and specificity of 66.4% (95% CI 43.9–83.3). Classic clinical indicators had poor accuracy for diagnosis of VAP. Reliance upon these indicators in isolation may result in misdiagnosis and potentially unnecessary antimicrobial use.

critical care medicine
Lung Protective Ventilation in Patients Undergoing Major Surgery: a Systematic Review Incorporating a Bayesian Approach

Zhongheng Zhang,Xiaoyun Hu,Xia Zhang,Xiuqi Zhu,Liqian Chen,Li Zhu,Caibao Hu,Bin Du

DOI: https://doi.org/10.1136/bmjopen-2014-007473

IF: 3.006

2014-01-01

BMJ Open

Abstract:OBJECTIVE:Protective ventilation (PV) has been validated in patients with acute respiratory distress syndrome. However, the effect of PV in patients undergoing major surgery is controversial. The study aimed to explore the beneficial effect of PV on patients undergoing a major operation by systematic review and meta-analysis.SETTING:Various levels of medical centres.PARTICIPANTS:Patients undergoing general anaesthesia.INTERVENTIONS:PV with low tidal volume.PRIMARY AND SECONDARY OUTCOME MEASURES:Study end points included acute lung injury (ALI), pneumonia, atelectasis, mortality, length of stay (LOS) in intensive care unit (ICU) and hospital.METHODS:Databases including PubMed, Scopus, EBSCO and EMBASE were searched from inception to May 2015. Search strategies consisted of terms related to PV and anaesthesia. We reported OR for binary outcomes including ALI, mortality, pneumonia, atelectasis and other adverse outcomes. Weighted mean difference was reported for continuous outcomes such as LOS in the ICU and hospital, pH value, partial pressure of carbon dioxide, oxygenation and duration of mechanical ventilation (MV).MAIN RESULTS:A total of 22 citations were included in the systematic review and meta-analysis. PV had protective effect against the development of ALI as compared with the control group, with an OR of 0.41 (95% CI 0.19 to 0.87). PV tended to be beneficial with regard to the development of pneumonia (OR 0.46, 95% CI 0.16 to 1.28) and atelectasis (OR 0.68, 95% CI 0.46 to 1.01), but statistical significance was not reached. Other adverse outcomes such as new onset arrhythmia were significantly reduced with the use of PV (OR 0.47, 95% CI 0.48 to 0.93).CONCLUSIONS:The study demonstrates that PV can reduce the risk of ALI in patients undergoing major surgery. However, there is insufficient evidence that such a beneficial effect can be translated to more clinically relevant outcomes such as mortality or duration of MV.TRIAL REGISTRATION NUMBER:The study was registered in PROSPERO (http://www.crd.york.ac.uk/PROSPERO/) under registration number CRD42013006416.
Aerosolized Antibiotics for Ventilator-Associated Pneumonia: a Pairwise and Bayesian Network Meta-Analysis

Feng Xu,Lulu He,Luanqing Che,Wen Li,Songmin Ying,Zhihua Chen,Huahao Shen

DOI: https://doi.org/10.1186/s13054-018-2106-x

IF: 15.1

2018-01-01

Critical Care

Abstract:Aerosolized antibiotics have been proposed as a novel and promising treatment option for the treatment of ventilator-associated pneumonia (VAP). However, the optimum aerosolized antibiotics for VAP remain uncertain. We included studies from two systematic reviews and searched PubMed, EMBASE, and Cochrane databases for other studies. Eligible studies included randomized controlled trials and observational studies. Extracted data were analyzed by pairwise and network meta-analysis. Eight observational and eight randomized studies were identified for this analysis. By pairwise meta-analysis using intravenous antibiotics as the reference, patients treated with aerosolized antibiotics were associated with significantly higher rates of clinical recovery (risk ratio (RR) 1.21, 95% confidence interval (CI) 1.09–1.34; P = 0.001) and microbiological eradication (RR 1.42, 95% CI 1.22–1.650; P < 0.0001). There were no significant differences in the risks of mortality (RR 0.88, 95% CI 0.74–1.04; P = 0.127) or nephrotoxicity (RR 1.00, 95% CI 0.72–1.39; P = 0.995). Using network meta-analysis, clinical recovery benefits were seen only with aerosolized tobramycin and colistin (especially tobramycin), and microbiological eradication benefits were seen only with colistin. Aerosolized tobramycin was also associated with significantly lower mortality when compared with aerosolized amikacin and colistin and intravenous antibiotics. The assessment of rank probabilities indicated aerosolized tobramycin presented the greatest likelihood of having benefits for clinical recovery and mortality, and aerosolized colistin presented the best benefits for microbiological eradication. Aerosolized antibiotics appear to be a useful treatment for VAP with respect to clinical recovery and microbiological eradication, and do not increase mortality or nephrotoxicity risks. Our network meta-analysis in patients with VAP suggests that clinical recovery benefits are associated with aerosolized tobramycin and colistin (especially tobramycin), microbiological eradication with aerosolized colistin, and survival with aerosolized tobramycin, mostly based on observational studies. Due to the low levels of evidence, definitive recommendations cannot be made before additional, large randomized studies are carried out.
Influence of ventilator-associated tracheobronchitis on prognosis of patients with chronic obstructive pulmonary disease

Jing ZHANG,Ning SHEN,Qing-tao ZHOU,Ying LIANG,Li-na SUN,Yong-zhong NING,Hong ZHU,Bei HE

DOI: https://doi.org/10.11816/cn.ni.2015-141852

2015-01-01

Abstract:OBJECTIVE To explore the influence of ventilator-associated tracheobronchitis (VAT)on prognosis of patients with chronic obstructive pulmonary disease (COPD)so as to provide guidance for clinical treatment. METHODS A total of 136 COPD patients who were hospitalized the RICU for mechanical ventilation from Jan 2012 to Dec 2013 were enrolled in the study,among whom 13 patients with confirmed VAT were assigned as the VAT group,and 13 matched cases were set as the control group;the prognosis was compared between the two groups. RESULTS A total of 1 9 strains of bacteria have been isolated from the submitted specimens obtained from the 1 3 VAT patients,among which the multidrug-resistant bacteria accounted for 94.7% (18 strains ),and 7 strains were isolated from the control group,accounting for 77.8% (P<0.05).There were 6 (46.2%)cases of mixed in-fections in the VAT group and 3 (23.1%)cases in the control group (P<0.05).The Pseudomonas aeruginosa, Acinetobacterbaumannii,and MRSA were the common pathogens causing VAT.The median mechanical ventila-tion duration was significantly extended in the VAT group (22 days),which was 13 days in the control group (P<0.05);the median length of ICU stay of the VAT group was 28 days,significantly longer than 16 days of the control group (P<0.05).In the VAT group,there were 6 (46.2%)patients who used antibiotics reasonably;the median mechanical ventilation duration of the patients who used antibiotics reasonably was 1 2 days,shorter than 20 days of the patients who did not use antibiotics reasonably;the median length of ICU stay of the patients who used antibiotics reasonably was 17 days,shorter than 23 days of the patients who did not use antibiotics reasona-bly,but there was no significant difference.CONCLUSION The VAT may lead to the extended mechanical ventila-tion duration and length of ICU stay,and appropriate initial drug therapy can improve the prognosis of the pa-tients.
Early Versus Late Tracheotomy In Icu Patients A Meta-Analysis Of Randomized Controlled Trials

Hongsheng Deng,Qiang Fang,Kun Chen,Xiaoling Zhang

DOI: https://doi.org/10.1097/MD.0000000000024329

IF: 1.6

2021-01-01

Medicine

Abstract:Background: This study aimed to quantitatively analyze the available randomized controlled trials (RCTs) and investigate whether early tracheotomy can improve clinical endpoints compared with late tracheotomy in critically ill patients undergoing mechanical ventilation. Methods: The electronic databases of PubMed, Embase, and the Cochrane library were systematically searched in August 2019. The investigated outcomes were calculated using relative risks (RRs) and standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs) through the random-effects model for categories and continuous data, respectively. Results: The electronic searches yielded 2289 records, including 15 RCTs comprising a total of 3003 patients and found to be relevant for the final quantitative analysis. The summary RRs that indicated early versus late tracheotomy were not associated with the risk of short-term mortality (RR: 0.87; 95% CI: 0.74-1.03; P = .114) and ventilator-associated pneumonia (RR: 0.90; 95% CI: 0.78-1.04; P = .156). Moreover, early tracheotomy was associated with shorter intensive care unit (ICU) stay (SMD: -1.81; 95% CI: -2.64 to -0.99; P < .001) and mechanical ventilation duration (SMD: -1.17; 95% CI: -2.10 to -0.24; P = .014). Finally, no significant difference was observed between early and late tracheotomy for hospital stay (SMD: -0.42; 95% CI: -1.36-0.52; P = .377). Conclusions: The present meta-analysis suggests that early tracheotomy can reduce the length of ICU stay and mechanical ventilation duration, but the timing of the tracheotomy was not associated with the short-term clinical endpoints in critically ill patients undergoing mechanical ventilation.
Value of bronchial amylase level for predicting ventilator associated pneumonia in intubated adults: a systematic review and meta-analysis

Tingzhen Xu,Qinkang Shen,Yuting He,Xiaozhuang Pan,Haijun Huang,Hua Xu

DOI: https://doi.org/10.1186/s12890-024-03393-z

IF: 3.1

2024-11-23

BMC Pulmonary Medicine

Abstract:The ability of bronchial amylase level for predicting ventilator associated pneumonia (VAP) has been extensively studied with conflicting results. This meta-analysis aimed to explore the value of bronchial amylase for predicting VAP in intubated adults.

respiratory system

Tuberkulose – nach wie vor aktuell

Impact Clinically Related Factors on the Outcomes of Ventilator-Associated Pneumonia

Do Probiotics Help Prevent Ventilator-Associated Pneumonia In Critically Ill Patients? A Systematic Review With Meta-Analysis

Fiberoptic bronchoscopy for the prevention of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials

Effect of bronchoalveolar lavage on the use of antibiotics in patients with severe pneumonia

Long-term Control of Intractable Supraventricular Tahycardia by Ventricular Pacing TABLE II 701 DRUG AND PACEMAKER TREATMENT

The preventive effect of inhaled antibiotic against ventilator-associated pneumonia: a systematic review and meta-analysis

Probiotics For Preventing Ventilator-Associated Pneumonia: A Systematic Review And Meta-Analysis Of High-Quality Randomized Controlled Trials

Effectiveness and safety of adjunctive inhaled antibiotics for ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials

Analysis of the risk factors and pathogenic bacteria of ventilator-associated pneumonia

[Interpretation of cholecystographic data].

Prophylactic Antibiotics Delivered Via the Respiratory Tract to Reduce Ventilator-Associated Pneumonia: A Systematic Review, Network Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials

Risk factors in patients with Acinetobacter baumanii ventilator-associated pneumonia

Efficacy of preventive interventions against ventilator-associated pneumonia in critically ill patients: An umbrella review of meta-analyses

Probiotics for the Prevention of Ventilator-Associated Pneumonia: A Meta-Analysis of Randomized Controlled Trials

Diagnosis of ventilator-associated pneumonia in critically ill adult patients—a systematic review and meta-analysis

Lung Protective Ventilation in Patients Undergoing Major Surgery: a Systematic Review Incorporating a Bayesian Approach

Aerosolized Antibiotics for Ventilator-Associated Pneumonia: a Pairwise and Bayesian Network Meta-Analysis

Influence of ventilator-associated tracheobronchitis on prognosis of patients with chronic obstructive pulmonary disease

Early Versus Late Tracheotomy In Icu Patients A Meta-Analysis Of Randomized Controlled Trials

Value of bronchial amylase level for predicting ventilator associated pneumonia in intubated adults: a systematic review and meta-analysis